Biotech startup Vima Therapeutics has announced a $100 million Series A funding round to accelerate the clinical testing of a daily pill designed to help patients with Parkinson’s disease and dystonia regain motor control.
Addressing unmet medical needs Incubated by Atlas Venture over three years ago, Vima is advancing its lead candidate, VIM0423. The company aims to provide a solution for the approximately 160,000 people in the U.S. suffering from isolated dystonia—a disabling condition characterized by involuntary muscle contractions. Currently, there are no FDA-approved oral medications specifically for isolated dystonia, leaving a significant gap in the treatment landscape.
Refining validated biological mechanisms VIM0423 selectively targets muscarinic cholinergic receptors, which are essential for regulating neurological functions like motor control. While older drugs targeting these receptors exist, they are often associated with poor tolerability and severe side effects. Vima’s therapy is engineered to be safer and pharmacologically enhanced, offering a potential alternative to current treatments like Botox injections or levodopa, which can lose efficacy over time.
Funding and future outlook The $100 million financing includes contributions from major investors such as Atlas, Frazier Life Sciences, and Canaan Partners. Vima plans to use the capital to move into mid-stage clinical trials, with data readouts expected in 2027. CEO Bernard Ravina, a trained neurologist, noted that the company’s name—Greek for “step”—reflects its mission to help patients restore their natural stride and movement.